XIENCE V Everolimus Eluting Coronary Stent System (EECSS) EXCEED: Evaluation of XIENCE V Catheterization Lab Endpoints and Excellence in Delivery.
Phase of Trial: Phase IV
Latest Information Update: 16 Oct 2015
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms EXCEED
- Sponsors Abbott Vascular
- 21 Oct 2009 Actual end date (October 2009) added as reported by ClinicalTrials.gov
- 21 Oct 2009 Status changed from active, no longer recruiting to completed as reportd by ClinicalTrials.gov
- 18 Apr 2009 Actual patient number (2517) added as reported by ClinicalTrials.gov.